Alex Pasteur is a member of the Board of Directors ofTenpoint Therapeutics. He has worked in healthcare investing since 2001 and isa Partner with F-Prime Capital based in London. Alex focuses oninvestments in therapeutics and healthcare IT. His portfolio includes AcaciaPharma (acquired by Eagle Pharmaceuticals, Inc.), Adaptimmune Therapeutics(NASDAQ: ADAP), ARTBio Inc., Arvelle Therapeutics GmbH (acquired by AngeliniPharma Spa), Castor (Ciwit BV), Genomics PLC, Nodthera Ltd., Orchard Therapeutics(NASDAQ: ORTX), Oviva AG, Owkin Inc., Peptone Ltd., Pulmocide Ltd. and ShiftBioscience Ltd. Prior to joining F-Prime in 2012, Alex worked at MVM LifeScience Partners LLP in the USA and Europe.
Alex earned a MA in Natural Sciences from CambridgeUniversity and a PhD in Chemistry from Cambridge University.
